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Abstract
Purpose In breast cancer (BC), the duration of endocrine adjuvant therapies (AT) has been extended continuously up to 
10 years. We present an alternative explanation for the effect, which could enable shorter treatments.
Method The relevant literature on chemoprevention and (neo-)adjuvant therapy was reviewed. Data for initiation and growth 
of primary and contralateral BCs and their metastases (MET) were considered. Also, population-based data from the Munich 
Cancer Registry for MET-free survival, time trends of MET patterns, and survival achieved by improved ATs are used to 
estimate all events in the long-term follow-up.
Results Extended ATs (EAT) that continue after 1, 2, or 5 years reduce mortality only slightly. The effect is delayed, occur-
ring more than 5 years after extension. EATs does not affect the prognosis of 1stBCs, they preventively eradicate contralateral 
2ndBCs and thus their future life-threatening METs. Because chemoprevention can eradicate BCs from the smallest clusters 
to almost detectable BCs, ATs can be temporarily suspended without imposing harm. Results equal to EATs can be achieved 
by short-term ATs of the 1stBC and by repeated neo-ATs targeted at the indefinitely developing 2ndBCs. Considering this 
potential in de-escalation, a 70–80% reduction of overtreatment seems possible.
Conclusion Knowledge of initiation and growth of tumors with known effects of neo-ATs suggest that intermittent endocrine 
ATs may achieve the same results as EATs but with improved quality of life and survival because of fewer side effects and 
better compliance. The challenge for developments of repeated ATs becomes: how short is short enough.
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Abbreviations
(E)AT  (Extended) adjuvant endocrine therapy
(1st/2nd) BC  (First/second) breast cancer
MET  Metastasis
TC  Tumor cell
VD  Volume doubling
Introduction
The goal of adjuvant therapies (ATs) is to reduce BC mortal-
ity. This is only possible by reducing life-threatening metas-
tases (METs), either by eradication or prevention. ATs have 
improved the prognosis of BC significantly over the past 
decades. 15-year tumor-specific survival should now exceed 
80% in comparison to 55% decades ago (Hölzel et al. 2017; 
Noone et al.; Welch et al. 2016). Endocrine ATs with tamox-
ifen and aromatase inhibitors showed an additional delayed 
survival benefit of less than 3% when extended to 5, 10 and 
more years (Bartlett et al. 2019; Davies et al. 2013; Goss 
et al. 2016; Gray 2013). This broad range of treatments has 
been considered extended AT (EAT) and guidelines already 
recommend 10 years of ongoing ATs (Burstein et al. 2019; 
Cardoso et al. 2019). Analysis of population-based data from 
the Munich Cancer Registry (Munich Cancer Registry) with 
long-term follow-up and changing MET patterns (Hölzel 
et al. 2017) have revealed principles of MET that suggest a 
critical review of EATs. The aim of this review is to explain 
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the proven benefit of EAT and to discuss functionally equiv-
alent AT strategies of intermittent ATs based on principles 
of tumor biology and empirical knowledge.
Methods
The article is based on a review of pertinent randomized 
controlled trials and meta-analysis of BC mortality to be 
considered for explaining the effect of EATs. First, the 
effects of neoadjuvant and ATs are considered. In ATs, we 
focus on the important distinction between the effects of 
delayed AT versus EATs. The second major focus concerns 
the initiation and growth of BCs and their METs. Chemopre-
vention is particularly relevant, because it provides data for 
the risk reduction of first and second BCs (1stBC/2ndBC) 
and for their growth duration.
Third, population-based data of the Munich Cancer Reg-
istry (MCR) are taken into account, whose versatile analysis 
ultimately led to the results presented herein, including the 
generation of the hypothesis that EAT maybe considered 
as overtreatment. We consider MET-free survival with a 
follow-up of 20 years and more, as well as time trends of 
the MET pattern and survival achieved by improved ATs. 
Analyses of MCR data have revealed relevant principles 
of MET and their treatment. Known data on the incidence 
of 1st/2ndBCs are also considered. These data and com-
binations of the effects of short-, long-term, delayed and 
preventive neo-ATs provide an explanation for the remark-
able delay in effect of EATs.
Results
Growth and initiation of breast cancer
Growing BCs can be described in four ways, by the number 
of tumor cells (TC), the duration of growth, the diameter of 
BCs and a molecular timeframe which distinguish phases 
with relevant mutations that disseminated TCs can inherit 
(Fig. 1a) (Yates et al. 2017). The growth of BCs has been 
estimated from mammography screening. For 60–70 year old 
patients, the median volume doubling (VD) time for tumor 
growth from 10 to 20 mm is 143 days, with a variation from 
65 to 308 days for the 25th and 75th percentile (Weedon-
Fekjaer et al. 2008). Applying these percentiles, a pT1a-
BC of 3 mm diameter would grow to a pT2-BC of 28 mm 
(the average of pT2) after 9.6 VDs within 1.7/3.8/8.2 years, 
respectively. The biennial screening with 20–25% interval 
cases confirms the variability.
If we assume a constant growth with these three percen-
tiles from the first TC, then a pT1c-BC will be reached after 
approximately 31.5 VDs or after 5.6/12.3/26.6 years. Pop-
ulation-based estimates reveal only about 7% fast-growing 
triple negative BCs, that is, even the growth rate of hor-
mone receptor positive (HR +) BCs varies by a factor of 
10 and more. These growth rates are plausible, because in 
Fig. 1  Initiation of metastases. 
Growing BCs (a) can initiate 
metastases (c, d), true local 
recurrences (e), positive lymph 
nodes (f) over time through 
dissemination of heterogeneous 
tumor cells (b). If not diagnosed 
synchronously, these secondary 
foci as well as 2ndBC (g) are 
already prevalent at diagnosis 
(h) and can be affected by ATs 
which are short compared to the 
growth duration of METs. TC 
tumor cell, TD tumor diameter, 
MET metastasis, AT adjuvant 
therapy, BCS breast conserving 
surgery
A: primary Tumor pT1c (diagnosis) pT-category
2. TD (mm)
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prevention trials the incidence reduction persists for at least 
15 years after the end of chemoprevention (Cuzick et al. 
2015). Therefore, contralateral 2ndBCs are already prevalent 
and may be diagnosed within the next 12.3 years after the 
removal of the 1stBC, 2% synchronous BCs are the first of 
them. 2ndBCs that appear after 12.3 years are increasingly 
initiated year after year following the removal of the 1stBC 
(Fig. 1g).
Initiation and growth of MET
The initiation of METs can be read from survival data. 
According to our data, the tumor-specific 15-year survival 
of pT1- and pT2-BCs was at 76% and 53% in the period 
1988–1997. Therefore, when a pT1c-tumor with a diameter 
of 15 mm is reached, at least 24% already had early initi-
ated METs. However, more than 23% additional METs will 
be initiated while growing up to 28 mm, which totals 47% 
METs that could not be eradicated by former use of ATs. A 
Gompertz function can be fitted for the S-shaped relation of 
tumor diameter and tumor-specific mortality, which results 
as the complement to 100% in the following: relative 15-year 
survival (%) = 100 − 58.39 × exp(− 4.46 × exp(− 0.071 × 
TD)) for tumor diameter (TD) ≤ 90 mm (Engel et al. 2019). 
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Fig. 2  Growth trajectories (GT) for BCs and METs. The time scales 
(median growth time 8  years for METs and 12  years for 2ndBCs) 
distinguishes times before and after BC diagnosis. Early initiated, 
synchronously diagnosed and no longer eradicable METs (red GTs), 
a median GT (brown dotted) and a late-initiated GT (green) are out-
lined. The age scale represents the age of prevalent METs at BC diag-
nosis. In addition, age distributions of METs are outlined in patient 
cohorts with immediate or delayed onset of ATs. Also outlined is the 
short duration of today’s ATs (black and green rectangle) compared 
to the growth period of METs. With the time scale for 2ndBCs, GTs 
are to be interpreted analogously. The dotted GTs represents 2ndBCs 
initiated after BC diagnosis (BC breast cancer, MET metastasis, AT 






































Fig. 3  Distribution functions of MET-free intervals. The dependency 
on hormone receptor status from BCs and on time periods with differ-
ent follow-up is to be considered (n = 6636 of T-N-M0 BCs)
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0–1.5% additional METs which are diagnosed in a median 
time span of 28 months (Munich Cancer Registry) before 
death.
Initiation, growth and treatment effects can be explained 
by growth trajectories, with a log scale for the number of 
TCs in relation to time (Fig. 2). Two growth sections need 
to be distinguished; before and after the diagnosis of a BC. 
METs of primary advanced BCs have grown after initia-
tion parallel to the BC and are diagnosed simultaneously. 
In primary M0 findings, the last MET initiations take place 
shortly before the BC removal. The sum of growth times 
before and after diagnosis are the same as for a median MET 
initiation. The distribution function of the MET-free survival 
time (Fig. 3) results in a median time of about 4 years. Taken 
together, a MET should grow a median of 8 years before its 
detection, or 93 days for one VD (Hölzel et al. 2010). This 
is long compared to the few months of AT regimes which 
act on MET (Fig. 2).
This MET process is correct as long as there is no initia-
tion of METs after R0 resections (DeMichele et al. 2017). 
But it is a contradiction to the dormancy hypothesis, accord-
ing to which METs can be initiated with time delays. But 
this explanation is not plausible. If circulating or dormant 
TCs could initiate delayed METs, then the shortening of 
each AT from years to a few months would have shown 
disadvantages, but until today, none have been reported. In 
addition, a long delay in initiated METs would have to be 
more often fast-growing triple negative tumors (Fig. 3). That 
is also not true, and therefore, TCs most likely do not cause 
clinically relevant METs after BC removal.
Effects of neoadjuvant and adjuvant therapies
Despite successful ATs, the survival after MET has not 
greatly improved and has now a median of about 28 months. 
Improving survival means successfully targeting occult 
METs. METs of HR + BCs grow slower than HR-BCs. 
About 50/90% of MET of HR + BCs occur within a MET-
free period of 5.6/15 years in comparison to 2.5/8.5 years for 
HR- BCs (Fig. 3). AT trials show no effect in the first few 
months. A possible reason is the exclusion of advanced BCs 
by staging, so that the remaining MET need more time up to 
detection (Fig. 2). Since diagnosed METs remain ineradica-
ble, this also applies to these larger undetected METs which 
occur in the first few months following BC diagnosis. Only 
then, after about 6 months or 1–2 VDs of METs do MET-
free survival curves open like scissors. The mortality reduc-
tion is delayed for another 28 months. Even if treatments 
lasted only 1 year, there was a reduction in METs after 5 
and 10 years (Early Breast Cancer Trialists’ Collaborative 
Group 1992).
The effectiveness of ATs is also manifested in delayed 
onset. Even a short delay of AT by 2 months after surgery 
leads to worse outcomes, because some prevalent METs 
grow to a no longer eradicable size in that short period of 
time, which is otherwise prevented by ATs by the annihila-
tion of METs within one VD (Gagliato et al. 2014; Yung 
et al. 2020). The distribution d1, outlined in Fig. 2 represents 
a cohort of patients in whom METs were continuously initi-
ated. At BC diagnosis, there are occult METs, from smallest 
clusters to almost detectable foci. The altered age structure 
of occult METs when initiations of AT are delayed describes 
distribution d2 with less tiny and more already detected 
METs.
Two studies show the effect of delayed starts of tamoxifen 
treatment after 2–5 years of tumor-free survival (Delozier 
et al. 2000; Veronesi et al. 2010). In a cohort of patients, 
when ATs start after a 5 year delay, almost 50% of all 
patients who are expected to develop METs during the first 
5 years are already excluded (Fig. 3). The effect of these 
delayed ATs on METs which are still occult after 5 years is 
similar to the scissors-like opening of immediately initiated 
ATs for all METs. However, there are no longer small TC 
clusters, because they have grown in size during the time of 
the treatment delay. This comparability confirms that occult 
METs of various ages were eradicated very quickly by ATs 
until they reach a no longer eradicable size.
Effects of extended adjuvant endocrine therapies
Studies investigating EATs up to 10 years (Bartlett et al. 
2019; Davies et al. 2013; Goss et al. 2016; Mamounas et al. 
2019) showed no survival effect for 5 years. This implies 
that EATs have no effect on METs of 1stBCs, although 
55% or 25% of METs will occur after 5 or 10 years, respec-
tively (Fig. 3). The ineffectiveness is plausible if there are 
resistant METs. But there is no tumor biology model so 
far that explains delayed eradication of METs. That is why 
the question arises, which effect will be achieved by the 
extension of ATs from 1 or 2 years to 5 years. 1–2 years 
of ATs was shown to improve survival even after 10 years 
(Early Breast Cancer Trialists’ Collaborative Group 1998; 
Ekholm et al. 2016). Comparisons of 2 versus 5 years of 
tamoxifen(Swedish Breast Cancer Cooperative Group 1996) 
and also placebo-controlled comparisons after 2 years of 
AT (Rutqvist and Johansson 2007) show that survival does 
not change as was also the case of immediate receipt of 
AT after 1 year. Additionally, the extension of ATs after 
1 or 2 years have a delayed effect as in the 5/10-year com-
parisons, although 95 or 85% of METs occur later (Fig. 3) 
(Bartlett et al. 2019; Davies et al. 2013). A delay in MET 
eradication of more than 5 years is also evident in the 5-year 
placebo comparison of tamoxifen (Early Breast Cancer Tri-
alists’ Collaborative Group 2011). Therefore, the phase of 
more than 5 years of ineffectiveness of EATs is very likely to 
be constant and transferable with EATs used after one year.
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Effects of successful adjuvant therapies 
over decades
Changes in MET patterns observed in the MCR over decades 
of successful AT use is an important aspect (Hölzel et al. 
2017). In comparison to MET patterns of earlier decades 
and today’s primary advanced BCs, bone and lung METs 
have been reduced by about 50% and 30%, respectively. 
METs are destroyed proportionally from the smallest clus-
ter to a non-eradicable MET size. Alternatively, a clinically 
relevant reduction of liver or CNS METs is not recogniz-
able. Therefore, the inability of ATs to act equivocally in 
any micro-environment of MET is one limitation of today’s 
ATs. Another limitation is that even the smallest clusters 
show acquired resistance, because even very late bone or 
lung MET occur which would have to have been very small 
during AT. Of particular note is that the historical success 
of ATs is almost independent of BC size. It is achieved in 
BCs with few positive lymph nodes, the proportion of which 
is largely the same for larger BCs (Engel et al. 2019; Welch 
et al. 2016).
Effects of chemoprevention
Information about the growth period of BCs demonstrates 
that 1st/2ndBCs are prevalent over many years. Therefore, 
chemoprevention acts as a neo-AT for already initiated or 
newly during prevention initiated BCs. Since the effect of 
prevention already occurs within a few months (Cuzick et al. 
2010) and continues even after the completion in the 5th year 
without risk change for more than 10 years, prevalent BCs 
of all sizes are most likely eradicated in 1–2 VDs of BCs, 
as are METs (Cuzick et al. 2015). This raises the important 
question of the necessary duration and the rationale of an 
effective prevention. Regardless of the duration, after the 
end of any prevention, new BCs develop because the risk of 
BCs continues throughout life (Fig. 2).
Discussion
Three types of results have been considered: initiation and 
growth of BCs and METs with their VD times, the effects 
of randomized trials on adjuvant, neoadjuvant, extended and 
preventive therapies, and population-based data on MET-
free survival along with changing MET patterns. This avail-
able evidence results in the following six statements:
First, if the start of ATs is delayed by even a few months 
or 1, 2 or 5 years, they will act on the then still prevalent 
occult METs in the same way they would if immediately 
starting ATs (Delozier et al. 2000; Veronesi et al. 2010). But 
if ATs are prolonged after 1, 2, 5 or 10 years, no comparable 
short-term effect on occult METs is achieved, but rather only 
a delayed effect after 5 and more years occurs.
If EATs cannot reduce the 30% MET from 5 to 10 years, 
then this should also true for the 25% METs from the 10th 
year. It follows that EAT does not reduce METs of the 1stBC 
(Fig. 3).
Second, the worse outcome after a short delay of ATs 
and the 5-year of ineffectiveness when AT is prolonged 
means, that eradicable METs are quickly destroyed and non-
eradicable METs are resistant. The studies show that METs 
decrease in the first year, mortality delayed by MET related 
survival only in the third year. BCs and METs are destroyed 
shortly after the respective 1–2 VDs. This evidence can 
already be read from the studies of the 1980s with tamox-
ifen 1–2 years (Early Breast Cancer Trialists’ Collaborative 
Group 1992, 1998).
Third, EATs also act as neo-ATs on occult 2ndBCs. Three 
effects are to be distinguished. Most importantly, about 50% 
of 2ndBCs can be eradicated along with their existent and/or 
future METs (Blok et al. 2018; Early Breast Cancer Trialists’ 
Collaborative Group 1998; Goss et al. 2016). As with neo-
ATs, only METs of 2ndBCs can be eradicated and thirdly, 
only the 2ndBC is eradicated. Resistant METs are then most 
commonly assigned to the 1stBC, but they are cancer of 
unknown, or more precisely, of already eradicated primary 
tumors.
Fourth, the magnitude of the delayed effect of EATs 
seems to be the same regardless of whether ATs are extended 













































Fig. 4  Effects of EATs by reducing METs from 2ndBCs. The cumu-
lative incidence of METs (black dotted line) is caused by 1stBCs and 
2ndBCs. If 2ndBCs (blue line) are reduced by 50% by EATs (red 
line), then their METs are also prevented (grey shaded area). Approx-
imately, 4–5 years after the onset of EATs, the reduction in MET risk 
could become observable because of the BC’s growth variability
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after 1, 2, 5 or 10 years and is independent from decreasing 
hazard rates of METs of 1stBCs (Fig. 3). The reason is the 
incidence of BCs which does not vary much after the age of 
55 years, at which point most BC patients are in long-term 
follow-up (Munich Cancer Registry; Noone et al.). Constant 
incidences should also apply to the 2ndBCs. Therefore, the 
delayed constant effect of EATs is due to the effective neo-
AT on any subsequent 2ndBCs (Fig. 4).
Fifth, regarding the size of the effect, it should be noted 
that the risk for 2ndBCs is greater than that for 1stBCs. 
This increased risk is a surrogate for inherited mutations 
(Metcalfe et al. 2004; Michailidou et al. 2017). Just a three-
fold risk(Chen et al. 1999) results in a cumulative 2ndBC 
incidence of approximately 17% after 15 years. It fits the 
magnitude of these EATs effects (Fig. 4) (Chaudary et al. 
1984; Gierach et al. 2016). Subgroups with classical Gail 
risk factors also reach such a magnitude for the 1stBC. The 
MET risk reduction should also be particularly large because 
the 2ndBCs are not yet detectable and if at all have initiated 
only small single METs.
Sixth, the duration of inefficiency of EATs is important 
to be considered. METs and subsequent BC-related death 
can occur 20 years after primary ATs (Fig. 3) (Pan et al. 
2017). Therefore, mortality is dominated in EAT studies by 
the MET risk of 1stBCs with a delayed small improvement, 
which is postponed more than 5 years for each successive AT 
extension. This small EAT effect provides an insight into the 
tumor process: initiation of BCs up to tumor-related death 
can occur in HR + BCs within 10 years.
EATs work because they prevent METs from contralateral 
2ndBCs. The assessment of the effect is made more difficult 
when the cumulative incidence of METs or mortality is pre-
sented in EAT trials with a time lag up to the prolongation 
of AT and not from diagnosis (Davies et al. 2013). Figure 4 
outlines the current incidence of METs from both 1stBC and 
2ndBC, and the expected effect of an EAT extended from 
the first year onwards. Consequences of 10 year of EATs 
show a simulation with today’s survival (Fig. 5). The hazard 
ratio of 0.7 is formally correct from the 10th year on (Davies 
et al. 2013). But for shared decision making, full information 
must be provided about all events, in particular because the 
benefits of 15 years of EATs have already been pointed out 
(Harbeck et al. 2019). This also includes the many risks of 
endocrine ATs such as flush, osteoporosis, or fractures and 
the elaborate efforts to prevent and control side effects. Not 
even 50% of patients complete a 5-year therapy, indicating 
the burden of EATs.
EATs do not present a new mechanistic principle of 
action. They act like any AT, but on newly initiated, and 
eradicable 2ndBCs, which develop year after year in 1stBC 
patient cohorts. Because the historical success of AT is inde-
pendent of tumor size (Engel et al. 2019; Welch et al. 2016), 
it is not plausible to recommend EAT depending on the risk 
of recurrence of the 1stBC (Burstein et al. 2019) but rather 
on the risk and growth rates for 2ndBCs, which should be 
independent of the prognosis of the 1stBC.
Intermittent endocrine therapies
The improvement of 2.8% survival by EATs most likely 
comes from eradication of 2ndBCs. Immediately initi-
ated ATs also have a chemopreventive effect on prevalent 
2ndBCs and, like the METs of the 1stBCs, are quickly 
destroyed. Extension of ATs cannot improve the prognosis 
of the 1st and prevalent 2ndBCs. However, year after year, 
new 2ndBCs are initiated, which EATs then always act on 
for all future 2ndBCs. This continuous use of EAT prior to 
a possible future initiation of 2ndBC could be considered 
misuse and overtreatment. This leads us to a new treatment 
paradigm with intermittent treatments and the question: how 
short is short enough.
A change of perspective is difficult if randomized trials 
with extended ATs show improvements in survival. In addi-
tion, shorter treatment durations are generally cautiously 
discussed because hope and interest are more focused on 
increasing the effect with prolonged therapies (Cameron 
et al. 2017). In particular, early animal experiments sug-
gested long durations for chemoprevention and ATs, which 
showed “…that BC development is best inhibited in the 
constant presence of an anti-oestrogen… and … reduction 
in the number and sizes of mammary tumors developing 
during continuous therapy” (Jordan and Allen 1980). Such 
a promising possibility to block the carcinogenic process 
can hamper. Yet in hindsight, the relation of BC and MET 
growth periods, the length of the therapeutic window and 
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Fig. 5  Simulations with 2 × 3500 patients with the expected mortal-
ity* and the small effect after 10 years. The survival is shown from 
the beginning with the common ATs, from randomization of the EAT 
(red, control green) after 5 years and from 10 years onward. *Mortal-
ity was simulated using the distribution in Fig. 3
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then as they are today and were not thoroughly considered 
in the transfer to humans.
The available evidence suggests that after first ATs that 
successfully target prevalent METs of the 1stBCs as well 
as prevalent 2ndBCs, therapy-free intervals should follow 
before ATs are repeated as neo-AT against newly initiated 
2ndBCs. The duration of the break has already been sug-
gested in the ATLAS trial, because almost no METs occur 
in the first 5 years, a 5-year interval subdivided into 1–1.5-
year treatment intervals, and 4–3.5-year treatment-free peri-
ods. ATs repeated after the break will chemopreventively 
eradicate 50% of new initiated BCs. The short treatment is 
sufficient, because the available endocrine therapies such as 
those that target e.g. HER2(Cameron et al. 2017) also have 
fast responses within few VDs times.
Such changes are already suggested. One study is testing 
an extended intermittent use of AI with 3 month therapy-free 
intervals each year after completion of 4–6 years of endo-
crine ATs, a tentative step towards a paradigm shift with 
treatment de-escalation without disadvantages for patients 
(Blok et al. 2018; Colleoni et al. 2018; Gnant et al. 2018). 
Lack of difference between 7 and 10 years of treatments also 
shows that shorter treatments achieve the same effects. This 
advancement is also suggested by prevention studies (Cuz-
ick et al. 2015). After 5 years of prevention and an equally 
long therapy-free interval, a further prevention initiated from 
the 10th year on repeats the success. This is a convincing 
intermittent neo-AT of the 1stBC in high-risk patients and is 
equally applicable to BC patients with high risk of 2ndBCs. 
Only the intervals have to be adjusted.
The main question about endocrine ATs today is not “how 
long is long enough”(Smith et al. 2014) but “how short is 
short enough”, an experimental challenge that needs to be 
supported by further reviews and evaluation of observational 
data and that could promote logical evidence-based reason-
ing. The sequential use of aromatase inhibitors and tamox-
ifen should also be critically examined (Cuzick et al. 2010; 
Early Breast Cancer Trialists’ Collaborative Group 2015).
Conclusion
The result of EATs is evidence-based but not the inter-
pretation. The eradication of prevalent 2ndBCs and their 
future METs cause the effect of EAT and can be achieved 
with functionally equivalent intermittent ATs. This is logi-
cal when cause, effect and growth times of BCs and METs 
are considered together. Both small clusters as well as large 
occult foci can already be eradicated by neo-ATs at the 
beginning of treatment. Therefore, a reduction of treatments 
of 70–80% every 5 years seems possible. Shorter treatment 
durations would significantly reduce the many risks and 
improve quality of life. Considering the nearly 2 million 
new HR + BCs worldwide and about 14 million BC patients 
surviving for more than 10 years, this population burden 
alone obliges a critical discourse on the rationale of intermit-
tent (neo-) ATs and a reduction of overtreatment. Improved 
quality of life, a modified chemoprevention for women at 
high risk for 1stBC and even higher survival rates after the 
1stBC all appear achievable with shorter interval treatments, 
fewer side effects and thus better compliance.
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